For research use only
| Cat No. | ABC-TC0900 |
| Product Type | Human Pancreas Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Adenocarinoma |
| Product Code | Panc-10.05; Panc10.05; PANC-10-05; PANC 1005; PANC1005; Panc1005; Pa16C; PL12; PL-12 |
Panc 10.05 cell line is used for pancreatic cancer research, studying tumor progression, drug resistance, and cellular metabolism in cancer biology.
Panc 10. 05 is a human pancreatic ductal adenocarcinoma (PDAC) cell line established in 1992 from a primary pancreatic adenocarcinoma of an 81-year-old male patient. This cell line exhibits an epithelial-like morphology with adherent growth properties and a doubling time of approximately 20~30 hours. Panc 10. 05 harbors the KRAS G12D mutation—an oncogenic driver frequently observed in PDAC. Cytogenetic analysis reveals chromosomal instability typical of PDAC, with multiple genomic alterations. As well, they express epithelial markers including cytokeratin 7/18. Panc 10.05 is microsatellite-stable and lacks caveolin‑1 protein expression, which has been linked to epithelial–mesenchymal transition (EMT) and aggressive phenotype. The cell line is tumorigenic in immunocompromised mice, making it suitable for in vivo studies of pancreatic cancer progression.
| Product Code | Panc-10.05; Panc10.05; PANC-10-05; PANC 1005; PANC1005; Panc1005; Pa16C; PL12; PL-12 |
| Species | Human |
| Cat.No | ABC-TC0900 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
Panc 10. 05 cell line serves as a valuable tool for pancreatic cancer research, particularly for evaluating therapeutic strategies targeting KRAS-driven oncogenesis. Its genetic profile and tumorigenic behavior make it an effective model for assessing cell proliferation, apoptosis and tumor growth inhibition in response to experimental treatments. Furthermore, Panc 10. 05 is suitable for xenograft studies, where its moderate tumorigenicity supports the preclinical evaluation of potential anti-angiogenic agents, cytotoxic compounds and targeted therapies. This cell line contributes to the advancement of precision medicine approaches in pancreatic ductal adenocarcinoma.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
